EcoDrugPlus

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSHHUG00000020067
Gene Symbol: ARAF
1 Cross references
184 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSHHUG00000003184
Gene Symbol: ABL1
1 Cross references
196 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSHHUG00000011163
Gene Symbol: ABL1
1 Cross references
196 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSHHUG00000023751
Gene Symbol: ADAM17
1 Cross references
204 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSHHUG00000047178
Gene Symbol: ADAM17A
1 Cross references
201 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSHHUG00000044039
Gene Symbol: ADAM17A
1 Cross references
202 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSHHUG00000002282
Gene Symbol: ADAMTS5
2 Cross references
192 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSHHUG00000044983
Gene Symbol: ADAMTS5
2 Cross references
193 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSHHUG00000000512
Gene Symbol: ADRM1
1 Cross references
194 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSHHUG00000009080
Gene Symbol: ADRM1
1 Cross references
185 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSHHUG00000030470
Gene Symbol: ADRM1
2 Cross references
186 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSHHUG00000048131
Gene Symbol: AKT1
1 Cross references
144 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).